<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>T, N, and M descriptors for the eighth edition of TNM classification for lung cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">T, N, and M descriptors for the eighth edition of TNM classification for lung cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">T, N, and M descriptors for the eighth edition of TNM classification for lung cancer</div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="4">T: Primary tumor</td> </tr> <tr> <td class="indent1">Tx</td> <td colspan="3">Primary tumor cannot be assessed or tumor proven by presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1">T0</td> <td colspan="3">No evidence of primary tumor</td> </tr> <tr> <td class="indent1">Tis</td> <td colspan="3">Carcinoma in situ</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1">T1</td> <td colspan="3">Tumor ≤3 cm in greatest dimension surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus (ie, not in the main bronchus)*</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent2"><strong>T1a(mi)</strong></td> <td colspan="3"><strong>Minimally invasive adenocarcinoma</strong><sup>¶</sup></td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent2"><strong>T1a</strong></td> <td colspan="3"><strong>Tumor ≤1 cm in greatest dimension</strong>*</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent2"><strong>T1b</strong></td> <td colspan="3"><strong>Tumor &gt;1 cm but ≤2 cm in greatest dimension</strong>*</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent2"><strong>T1c</strong></td> <td colspan="3"><strong>Tumor &gt;2 cm but ≤3 cm in greatest dimension</strong>*</td> </tr> <tr> <td class="indent1"><strong>T2</strong></td> <td colspan="3">Tumor &gt;3 cm <strong>but ≤5 cm</strong> or tumor with any of the following features:<sup>Δ</sup> <ul class="decimal_heading"> <li><strong>Involves main bronchus regardless of distance from the carina but without involvement of the carina</strong> </li> <li>Invades visceral pleura </li> <li><strong>Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung</strong> </li> </ul> </td> </tr> <tr> <td class="indent2"><strong>T2a</strong></td> <td colspan="3"><strong>Tumor &gt;3 cm but ≤4 cm in greatest dimension</strong></td> </tr> <tr> <td class="indent2"><strong>T2b</strong></td> <td colspan="3"><strong>Tumor &gt;4 cm but ≤5 cm in greatest dimension</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1"><strong>T3</strong></td> <td colspan="3"><strong>Tumor &gt;5 cm but ≤7 cm in greatest dimension</strong> or associated with separate tumor nodule(s) in the same lobe as the primary tumor or directly invades any of the following structures: chest wall (including the parietal pleura and superior sulcus tumors), phrenic nerve, parietal pericardium</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>T4</strong></td> <td colspan="3"><strong>Tumor &gt;7 cm in greatest dimension</strong> or associated with separate tumor nodule(s) in a different ipsilateral lobe than that of the primary tumor or invades any of the following structures: <strong>diaphragm</strong>, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, and carina</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">N: Regional lymph node involvement</td> </tr> <tr> <td class="indent1">Nx</td> <td colspan="3">Regional lymph nodes cannot be assessed</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1">N0</td> <td colspan="3">No regional lymph node metastasis</td> </tr> <tr> <td class="indent1">N1</td> <td colspan="3">Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1">N2</td> <td colspan="3">Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</td> </tr> <tr class="divider_bottom"> <td class="indent1">N3</td> <td colspan="3">Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">M: Distant metastasis</td> </tr> <tr> <td class="indent1">M0</td> <td colspan="3">No distant metastasis</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1">M1</td> <td colspan="3">Distant metastasis present</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent2">M1a</td> <td colspan="3">Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodule(s) or malignant pleural or pericardial effusion<sup>◊</sup></td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent2"><strong>M1b</strong></td> <td colspan="3"><strong>Single extrathoracic metastasis</strong><sup>§</sup></td> </tr> <tr class="divider_bottom" style="background-color: #eafaf1;"> <td class="indent2"><strong>M1c</strong></td> <td colspan="3"><strong>Multiple extrathoracic metastases in one or more organs</strong></td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Stage groupings</td> </tr> <tr> <td class="indent1">Occult carcinoma</td> <td>TX</td> <td>N0</td> <td>M0</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1">Stage 0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class="indent1" rowspan="2"><strong>Stage IA1</strong></td> <td><strong>T1a(mi)</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td><strong>T1a</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1"><strong>Stage IA2</strong></td> <td><strong>T1b</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td class="indent1"><strong>Stage IA3</strong></td> <td><strong>T1c</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1">Stage IB</td> <td>T2a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class="indent1">Stage IIA</td> <td>T2b</td> <td>N0</td> <td>M0</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1" rowspan="4">Stage IIB</td> <td><strong>T1a to c</strong></td> <td><strong>N1</strong></td> <td><strong>M0</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td><strong>T2a</strong></td> <td><strong>N1</strong></td> <td><strong>M0</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td>T2b</td> <td>N1</td> <td>M0</td> </tr> <tr style="background-color: #eafaf1;"> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class="indent1" rowspan="5">Stage IIIA</td> <td><strong>T1a to c</strong></td> <td><strong>N2</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td>T2a to b</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N1</td> <td>M0</td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1" rowspan="4">Stage IIIB</td> <td><strong>T1a to c</strong></td> <td><strong>N3</strong></td> <td><strong>M0</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td>T2a to b</td> <td>N3</td> <td>M0</td> </tr> <tr style="background-color: #eafaf1;"> <td><strong>T3</strong></td> <td><strong>N2</strong></td> <td><strong>M0</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td>T4</td> <td>N2</td> <td>M0</td> </tr> <tr> <td class="indent1" rowspan="2"><strong>Stage IIIC</strong></td> <td><strong>T3</strong></td> <td><strong>N3</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td><strong>T4</strong></td> <td><strong>N3</strong></td> <td><strong>M0</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td class="indent1" rowspan="2"><strong>Stage IVA</strong></td> <td><strong>Any T</strong></td> <td><strong>Any N</strong></td> <td><strong>M1a</strong></td> </tr> <tr style="background-color: #eafaf1;"> <td><strong>Any T</strong></td> <td><strong>Any N</strong></td> <td><strong>M1b</strong></td> </tr> <tr> <td class="indent1"><strong>Stage IVB</strong></td> <td><strong>Any T</strong></td> <td><strong>Any N</strong></td> <td><strong>M1c</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd">NOTE: Changes to the seventh edition are in bold.</div><div class="graphic_footnotes">TNM: tumor, node, metastasis; Tis: carcinoma in situ; T1a(mi): minimally invasive adenocarcinoma.<br/>* The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.<br/>¶ Solitary adenocarcinoma, ≤3 cm with a predominately lepidic pattern and ≤5 mm invasion in any one focus.<br/>Δ T2 tumors with these features are classified as T2a if ≤4 cm in greatest dimension or if size cannot be determined, and T2b if &gt;4 cm but ≤5 cm in greatest dimension.<br/><span class="lozenge">◊</span> Most pleural (pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor and the fluid is nonbloody and not an exudate. When these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor.<br/>§ This includes involvement of a single distant (nonregional) lymph node.</div><div class="graphic_reference">Reproduced from: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:39. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 109805 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
